Jazz Pharmaceuticals (NASDAQ:JAZZ) Given “Buy” Rating at Needham & Company LLC

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports. They presently have a $210.00 price target on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price would indicate a potential upside of 49.26% from the stock’s previous close.

JAZZ has been the subject of several other research reports. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Barclays reiterated an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. TD Cowen cut their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $182.47.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded up $1.74 during trading hours on Wednesday, reaching $140.69. 265,585 shares of the stock traded hands, compared to its average volume of 721,354. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a 50 day simple moving average of $127.31 and a two-hundred day simple moving average of $119.57. Jazz Pharmaceuticals has a 1 year low of $99.06 and a 1 year high of $148.06. The company has a market cap of $8.54 billion, a price-to-earnings ratio of 19.82, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $144.25, for a total transaction of $937,625.00. Following the completion of the transaction, the chief executive officer now owns 464,058 shares of the company’s stock, valued at approximately $66,940,366.50. This trade represents a 1.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares of the company’s stock, valued at $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,113 shares of company stock worth $2,551,834. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in JAZZ. Stephens Inc. AR boosted its stake in Jazz Pharmaceuticals by 16.1% in the 3rd quarter. Stephens Inc. AR now owns 5,563 shares of the specialty pharmaceutical company’s stock worth $620,000 after purchasing an additional 771 shares in the last quarter. Van ECK Associates Corp raised its holdings in Jazz Pharmaceuticals by 11.4% in the third quarter. Van ECK Associates Corp now owns 60,211 shares of the specialty pharmaceutical company’s stock worth $6,691,000 after buying an additional 6,157 shares during the last quarter. Philip James Wealth Mangement LLC bought a new position in shares of Jazz Pharmaceuticals in the third quarter worth approximately $830,000. CWA Asset Management Group LLC purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $3,197,000. Finally, Crossmark Global Holdings Inc. increased its position in shares of Jazz Pharmaceuticals by 23.6% during the third quarter. Crossmark Global Holdings Inc. now owns 5,083 shares of the specialty pharmaceutical company’s stock valued at $567,000 after acquiring an additional 970 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.